BIOCRYST TO RELEASE FOURTH QUARTER FINANCIALS ON FEBRUARY 1, 2001
The Company will conduct a conference call at 10:00 am EST on Thursday, February 1, which is open to the public. The conference call dial-in number is 1-800-289-0487, and the passcode number is 712450. The conference call will also be available by webcast on the Company's investor relations website, www.biocryst.com.
For those unable to listen at the designated time, a conference call replay will be available for two days following the conference call, from approximately 1:00 p.m EST on Thursday, February 1, 2001 to midnight Saturday, February 3, 2001. The conference call replay can be heard by dialing 1-888-203-1112 and entering passcode number 712450. The webcast will also remain available for replay over BioCryst's website until March 31, 2001.
Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of pharmaceuticals for the treatment of antiviral, inflammatory/autoimmune and cardiovascular diseases and disorders. BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as BCX-1812), is a neuraminidase inhibitor designed to treat and prevent viral influenza. The Company licensed this drug candidate to RWJPRI and Ortho-McNeil Pharmaceutical, Inc., both Johnson & Johnson (NYSE: JNJ) companies.